SRTS — Sensus Healthcare, Inc.

Sensus Healthcare, Inc. (SRTS) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Q4 2025 Revenues: $4.9 million, down from $31 million in Q4 2024, primarily due to reduced sales to the largest customer.
• Cost of Sales: $3 million, down from $6 million year-over-year.
• Gross Profit: $1.9 million (38.8% of revenues), compared to $7.1 million (54.2% of revenues) in Q4 2024.
• Net Loss: $3.2 million, or $0.19 per share, compared to a net income of $1.5 million, or $0.09 per share, in Q4 2024.
• Adjusted EBITDA: Negative $3 million, down from positive $1.9 million in Q4 2024.
• Full-Year 2025 Revenues: $27.5 million, down from $41.8 million in 2024.
• Full-Year Net Loss: $7.7 million, or $0.47 per share, compared to net income of $6.6 million, or $0.41 per share, in 2024.
• Cash Position: $22.1 million in cash and cash equivalents, with no debt.

2. Strategic Updates and Business Highlights:

• CPT Codes: Received exclusive CPT codes for SRT and IGSRT technologies, enhancing reimbursement clarity for nonmelanoma skin cancer treatments.
• Sales Strategy: Plans to expand the sales force in Q1 2026 to drive market education and lead conversions.
• International Growth: Continued strong demand, particularly in China, Taiwan, and potential expansion into Brazil and other markets.
• Fair Deal Agreement Program: Increased utilization, with treatments up over eightfold year-over-year and a significant rise in patients treated.

3. Forward Guidance and Outlook:

• Q1 2026 Expectations: Anticipate revenues to exceed Q4 2025 levels, excluding contributions from the largest customer.
• 2026 Objectives: Aim for full-year profitability, supported by new reimbursement codes and a diversified customer base.

4. Bad News, Challenges, or Points of Concern:

• Declining Revenue: Significant drop in revenues and gross profit compared to prior year, primarily due to reduced sales to the largest customer.
• Customer Concentration: Reliance on a single large customer has been a challenge, though efforts are underway to diversify the customer base.
• FDA Approval Delays: Ongoing challenges with FDA approval for certain products, which may impact future growth.

5. Notable Q&A Insights:

• Customer Contributions: Future projections do not include contributions from the largest customer, which poses a risk but also potential upside if they resume orders.
• International Demand: Strong interest in SRT technology in Asia, particularly in China and Taiwan, with expectations for growth in other regions.
• Shift in Financing Preferences: Smaller practices are increasingly opting for outright purchases or leases rather than shared revenue models, driven by reimbursement clarity.
• Interest from Private Equity: Increased interest from private equity groups in light of clearer reimbursement pathways, indicating potential for future partnerships.

Overall, Sensus Healthcare is navigating a challenging financial landscape but is optimistic about future growth driven by new reimbursement codes and a diversified sales strategy.